
|Articles|March 3, 2008
Post-marketing liver injury reports lead to Tysabri PI update
Liver injury warnings added to natalizumab prescribing information.
Advertisement
Reports of markedly elevated serum hepatic enzymes and elevated total bilirubin in patients receiving natalizumab (
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
Embedded Pharmacists Are Vital Yet Underutilized in Diabetes Care
2
Executive Order Calls for Realignment of Childhood Vaccines
3
The Prodigious PBM Pivot: How Supply Chain Entities Will Move Forward After CAA 2026
4
Heat and Older Adults: What Pharmacists Need to Know
5





























































